Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients

21 Nov 2021

Abstract excerpt

Abstract There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for immunocompromised patients. In this study, we determined the neutralizing antibody response in 160 cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), after they received two doses of mRNA vaccines. Serum from 46 mRNA vaccinated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immunotherapy and Immune Responses
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34802457
DOI: 10.1186/s13578-021-00713-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patientsPMID 34802457Read ↗

Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL PatientsSemantic proximity Read ↗

Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity Read ↗

Immunogenicity of SARS-CoV-2 mRNA Vaccines in Patients with Cancer: Findings from an International Collaborative Cohort StudySemantic proximity Read ↗

Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concernSemantic proximity Read ↗

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE studySemantic proximity Read ↗

Durable tracking anti-SARS-CoV-2 antibodies of cancer patients recovered from COVID-19Semantic proximity Read ↗

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialSemantic proximity Read ↗

SARS-CoV-2 vaccination unmasks distinct immune dysfunctions across lymphoma subtypes and therapiesSemantic proximity Read ↗

Longitudinal Vaccine-Induced Humoral Immune Response in Cancer PatientsSemantic proximity Read ↗

Comprehensive analysis of immune responses in CLL patients after heterologous COVID-19 vaccinationSemantic proximity Read ↗

Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccinationSemantic proximity Read ↗

Impaired SARS-CoV-2 mRNA Vaccine Antibody Response in Chronic Medical ConditionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.